RHEL

Rhelion ships first batch of PEX010 psilocybin to USC for clinical trial use.

Rhelion advances IBEX011 to stability testing and settles $100,000 debt with shares.

Rhelion's Filament inks PEX010 supply deal for major psilocybin anxiety trial.

Rhelion signs Belgian supply deal for psilocybin, pending regulatory approval.

Rhelion will supply psilocybin for a UCSF-led Phase 2 trial starting November 2026.

Rhelion expands PEX010 supply for Italy’s first psilocybin depression trial.

Rhelion’s acquisition of Filament brings scale, but losses are widening and revenue is falling.

Rhelion touts a new US patent, but offers no financials or near-term commercial proof.

Rhelion's Filament inks a psilocybin supply deal, but financial impact remains unproven.

Rhelion touts a clinical supply deal and acquisition, but financial impact remains unproven.